Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (928) Arrow Down
Filter Results: (928) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (928)
    • People  (2)
    • News  (70)
    • Research  (779)
    • Events  (1)
    • Multimedia  (2)
  • Faculty Publications  (670)

Show Results For

  • All HBS Web  (928)
    • People  (2)
    • News  (70)
    • Research  (779)
    • Events  (1)
    • Multimedia  (2)
  • Faculty Publications  (670)
← Page 21 of 928 Results →
  • July 2009 (Revised May 2010)
  • Case

Pfizer: Letter from the Chairman (A)

By: Robert L. Simons and Natalie Kindred
This case explores maximizing shareholder value as a goal in executive decision making. Over a period of nine years, three different Pfizer CEOs make critical decisions intended to increase shareholder value. But the results are disappointing. To allow students to... View Details
Keywords: Decision Choices and Conditions; Corporate Accountability; Corporate Governance; Annual Reports; Business and Shareholder Relations; Value Creation; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Simons, Robert L., and Natalie Kindred. "Pfizer: Letter from the Chairman (A)." Harvard Business School Case 110-003, July 2009. (Revised May 2010.)
  • Web

Recruiting Partners - Health Care

Pharmaceuticals Alpha Edison AMAG Pharmaceuticals Amarin Corporation American Tinnitus Association American Well AmerisourceBergen Amgen, Inc. Amicoat AS Amicus Therapeutics Amnisure International LLC... View Details
  • December 2019
  • Case

The Business of Pain: Johnson & Johnson and the Promise of Opioids

By: Erik Snowberg, Trevor Fetter and Amy W. Schulman
This case is designed to provide an engrossing overview of stakeholder capitalism through a vigorous discussion of the conflicts that can arise when trying to serve multiple stakeholders. In 2007, Johnson & Johnson’s (J&J) subsidiary Janssen has to decide whether or... View Details
Keywords: Opioids; Addiction; Stakeholder Capitalism; Business and Stakeholder Relations; Product Launch; Decision Making; Ethics; Social Issues; Pharmaceutical Industry
Citation
Educators
Purchase
Related
Snowberg, Erik, Trevor Fetter, and Amy W. Schulman. "The Business of Pain: Johnson & Johnson and the Promise of Opioids." Harvard Business School Case 720-420, December 2019.

    Joey Ryu

    Joey (Won Jung) Ryu is a doctoral student in the Strategy unit at Harvard Business School. Her primary interests are strategic management, economics of innovation and entrepreneurship. Prior to joining HBS, Joey received her master's degree from Cornell University... View Details
    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
    • 01 Sep 2007
    • News

    Alfred D. Chandler Jr. Remembered

    Matsushita. That volume was followed in 2005 by Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries. “Such science-based View Details
    • October 2022
    • Case

    Cost Plus Drugs

    By: Alexander MacKay and James Barnett
    In September 2022, Mark Cuban Cost Plus Drugs Company CEO Alex Oshmyansky considered the future of the company. Cost Plus Drugs was a retailer for more than 340 generic oral medications, selling their drugs at significantly lower prices than typical pharmacies.... View Details
    Keywords: Business Ventures; Decision Making; Entrepreneurship; Ethics; Health; Markets; Social Enterprise; Society; Strategy; Health Care and Treatment; Business Divisions; Factories, Labs, and Plants; Health Industry; Health Industry; United States; Texas
    Citation
    Educators
    Purchase
    Related
    MacKay, Alexander, and James Barnett. "Cost Plus Drugs." Harvard Business School Case 723-362, October 2022.
    • December 2017 (Revised January 2018)
    • Case

    Alltech

    By: David E. Bell and Natalie Kindred
    Alltech was a Lexington, Kentucky–based producer of supplements for animal feed, with revenues of over $2 billion (projected to reach $3 billion in 2018), sales in 120 countries, 5,000 employees, and 100 manufacturing plants worldwide. For nearly four decades, Alltech... View Details
    Keywords: Alltech; United States; Agribusiness; Agriculture; Animal; Animal Agriculture; Animal Feed; Livestock; Family Business; Vertical Integration; Strategy; Growth; Feed Additives; Feed Supplements; Kentucky; Growth Strategy; Family Businesses; Animal-Based Agribusiness; Acquisition; Business Growth and Maturation; Business Model; Change Management; Trends; Governance; Entrepreneurship; Growth and Development; Intellectual Property; Leadership; Management; Markets; Organizational Culture; Private Ownership; Science; Quality; Risk and Uncertainty; Research; Sales; Agriculture and Agribusiness Industry; Agriculture and Agribusiness Industry; United States; Kentucky; Brazil; China
    Citation
    Educators
    Purchase
    Related
    Bell, David E., and Natalie Kindred. "Alltech." Harvard Business School Case 518-001, December 2017. (Revised January 2018.)
    • 17 Jan 2008
    • Working Paper Summaries

    Competition in Modular Clusters

    Keywords: by Carliss Y. Baldwin & C. Jason Woodard; Pharmaceutical; Pharmaceutical; Pharmaceutical; Pharmaceutical
    • March 2023 (Revised March 2023)
    • Case

    Roche: Innovation and Access to Healthcare

    By: George Serafeim, Susanna Gallani and Benjamin Maletta
    In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that had... View Details
    Keywords: ESG (Environmental, Social, Governance) Performance; Sustainable Finance; Growth Strategy And Execution; Sustainability Targets; Impact Evaluation; Healthcare Access; Healthcare Innovation; Healthcare Systems; Healthcare Operations; Finance; Strategy; Health Testing and Trials; Health Care and Treatment; Growth Management; Measurement and Metrics; Innovation Strategy; Corporate Social Responsibility and Impact; Health Industry; Health Industry; Switzerland; North America; Europe; Asia; Latin America; Africa
    Citation
    Educators
    Purchase
    Related
    Serafeim, George, Susanna Gallani, and Benjamin Maletta. "Roche: Innovation and Access to Healthcare." Harvard Business School Case 123-075, March 2023. (Revised March 2023.)
    • July 2001 (Revised August 2005)
    • Case

    Medicines Company, The

    By: John T. Gourville
    It is early 2001 and the Medicines Co. just received FDA approval to market Angiomax, a blood thinner to be used during angioplasties and heart procedures. It is intended to be a better alternative to Heparin, an 80-year-old drug that costs less then $10 per dose. The... View Details
    Keywords: Business Model; Change Management; Decision Choices and Conditions; Cost Management; Price; Product Marketing; Product Launch; Product Development; Risk and Uncertainty; Health Industry; Health Industry
    Citation
    Educators
    Purchase
    Related
    Gourville, John T. "Medicines Company, The." Harvard Business School Case 502-006, July 2001. (Revised August 2005.)
    • September 2010 (Revised July 2013)
    • Case

    Alnylam Pharmaceuticals: Building Value from the IP Estate

    By: Willy C. Shih and Sen Chai
    The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it... View Details
    Keywords: Patents; Lawsuits and Litigation; Rights; Competitive Strategy; Corporate Strategy; Biotechnology Industry; Biotechnology Industry; United States
    Citation
    Educators
    Purchase
    Related
    Shih, Willy C., and Sen Chai. "Alnylam Pharmaceuticals: Building Value from the IP Estate." Harvard Business School Case 611-009, September 2010. (Revised July 2013.)
    • May 1998 (Revised May 1999)
    • Case

    Biopure Corp.

    By: John T. Gourville
    It is early 1998 and Biopure Corp., a small biopharmaceutical firm with no sales revenues in its ten-year history, has just received government approval to release Oxyglobin, a revolutionary new "blood substitute" designed to replace the need for donated animal blood... View Details
    Keywords: Segmentation; Marketing Strategy; Engineering; Budgets and Budgeting; Sales; Transformation; Markets; Debates; Product Launch; Pharmaceutical Industry
    Citation
    Educators
    Purchase
    Related
    Gourville, John T. "Biopure Corp." Harvard Business School Case 598-150, May 1998. (Revised May 1999.)
    • Web

    Research - Health Care

    UAE for fibroids or adenomyosis were captured from electronic health record timestamps and... May 2024 Article Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms By: Caroline Marra... View Details
    • February 2024
    • Case

    Compass Pathways: Pioneering Psychedelic Treatment

    By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
    This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no... View Details
    Keywords: Commercialization; Corporate Strategy; Competitive Strategy; Product Launch; Health Testing and Trials; Research and Development; Laws and Statutes; Pharmaceutical Industry; Europe; United States; United Kingdom
    Citation
    Educators
    Purchase
    Related
    Zuzul, Tiona, Kisha Lashley, and Gamze Yucaoglu. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Case 724-412, February 2024.
    • February 2010 (Revised September 2011)
    • Case

    Roche's Acquisition of Genentech

    By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain
    Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details
    Keywords: Mergers and Acquisitions; Business Subsidiaries; Negotiation Offer; Organizational Culture; Corporate Strategy; Biotechnology Industry; Biotechnology Industry; Switzerland
    Citation
    Educators
    Purchase
    Related
    Baldwin, Carliss Y., Bo Becker, and Vincent Marie Dessain. "Roche's Acquisition of Genentech." Harvard Business School Case 210-040, February 2010. (Revised September 2011.)
    • June 2004 (Revised June 2006)
    • Supplement

    Vertex Pharmaceuticals: R&D Portfolio Management (A)

    By: Gary P. Pisano, Lee Fleming and Eli Strick
    Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will... View Details
    Keywords: Research and Development; Investment Portfolio; Pharmaceutical Industry
    Citation
    Purchase
    Related
    Pisano, Gary P., Lee Fleming, and Eli Strick. "Vertex Pharmaceuticals: R&D Portfolio Management (A)." Harvard Business School Supplement 604-101, June 2004. (Revised June 2006.)
    • 02 Mar 2010
    • First Look

    First Look: March 2

    innovation in a wide range of other industries, including pharmaceuticals and biotechnology, IT and telecommunications, defense, chemicals, and agriculture. We believe that there are valuable lessons in this research for the energy... View Details
    Keywords: Martha Lagace
    • Web

    Strategy Awards & Honors - Faculty & Research

    Industry Studies Association Annual Conference for “You've Got Mail! The Late 19th Century US Postal Service Expansion, Firm Creation, and Firm Performance” with Astrid Marinoni. Raffaella Sadun : Winner of the 2023 HBR Prize for the best... View Details
    • Web

    Request more information | HBS Courses | HBS Online

    Aerospace/Defense Agriculture Auto Communications E-Commerce E-Education Energy Entertainment Financial Services Food/Beverage Health/Medical Hospitality Insurance Manufacturing Non-Profit Pharmaceuticals Professional Services Retail... View Details
    • 27 May 2009
    • First Look

    First Look: May 27, 2009

    industry and services. Although each Mubadala investment is supposed to earn large returns, the strategy balances financial against "strategic" returns. ADIA and Mubadala are the institutional architecture to manage the wealth... View Details
    Keywords: Martha Lagace
    • ←
    • 21
    • 22
    • …
    • 46
    • 47
    • →
    ǁ
    Campus Map
    Harvard Business School
    Soldiers Field
    Boston, MA 02163
    →Map & Directions
    →More Contact Information
    • Make a Gift
    • Site Map
    • Jobs
    • Harvard University
    • Trademarks
    • Policies
    • Accessibility
    • Digital Accessibility
    Copyright © President & Fellows of Harvard College.